159 related articles for article (PubMed ID: 23643683)
1. Consensus Statement on medication use in multiple sclerosis by the Spanish Society of Neurology's study group for demyelinating diseases.
García-Merino A; Fernández O; Montalbán X; de Andrés C; Oreja-Guevara C; Rodríguez-Antigüedad A; Arbizu T;
Neurologia; 2013; 28(6):375-8. PubMed ID: 23643683
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
García Merino A; Ramón Ara Callizo J; Fernández Fernández O; Landete Pascual L; Moral Torres E; Rodríguez-Antigüedad Zarrantz A
Neurologia; 2017 Mar; 32(2):113-119. PubMed ID: 27157522
[TBL] [Abstract][Full Text] [Related]
3. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.
Meca-Lallana JE; Martínez Yélamos S; Eichau S; Llaneza MÁ; Martín Martínez J; Peña Martínez J; Meca Lallana V; Alonso Torres AM; Moral Torres E; Río J; Calles C; Ares Luque A; Ramió-Torrentà L; Marzo Sola ME; Prieto JM; Martínez Ginés ML; Arroyo R; Otano Martínez MÁ; Brieva Ruiz L; Gómez Gutiérrez M; Rodríguez-Antigüedad Zarranz A; Sánchez-Seco VG; Costa-Frossard L; Hernández Pérez MÁ; Landete Pascual L; González Platas M; Oreja-Guevara C
Neurologia (Engl Ed); 2024 Mar; 39(2):196-208. PubMed ID: 38237804
[TBL] [Abstract][Full Text] [Related]
4. [Current therapy of multiple sclerosis].
Antonio García Merino J
Med Clin (Barc); 2014 Dec; 143 Suppl 3():19-22. PubMed ID: 25732945
[TBL] [Abstract][Full Text] [Related]
5. [Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy].
García Merino A; Fernández O; Montalbán X; de Andrés C; Arbizu T
Neurologia; 2010; 25(6):378-90. PubMed ID: 20738958
[TBL] [Abstract][Full Text] [Related]
6. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society.
Henze T; Rieckmann P; Toyka KV;
Eur Neurol; 2006; 56(2):78-105. PubMed ID: 16966832
[TBL] [Abstract][Full Text] [Related]
8. [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines].
Lana-Peixoto MA; Callegaro D; Moreira MA; Campos GB; Marchiori PE; Gabbai AA; Bacheschi LA; Arruda WO; Gama PD; Melo AS; Rocha FC; Lino AM; Ferreira ML; Ataide L;
Arq Neuropsiquiatr; 2002 Sep; 60(3-B):881-6. PubMed ID: 12364967
[TBL] [Abstract][Full Text] [Related]
9. [Update of the treatment of multiple sclerosis].
Miyamoto K
Nihon Rinsho; 2013 May; 71(5):817-21. PubMed ID: 23777088
[TBL] [Abstract][Full Text] [Related]
10. Headache: What to ask, how to examine, and which scales to use. Recommendations of the Spanish Society of Neurology's Headache Study Group.
Gago-Veiga AB; Camiña Muñiz J; García-Azorín D; González-Quintanilla V; Ordás CM; Torres-Ferrus M; Santos-Lasaosa S; Viguera-Romero J; Pozo-Rosich P
Neurologia (Engl Ed); 2022 Sep; 37(7):564-574. PubMed ID: 30929913
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group.
García-Ull J; González-García N; Torres-Ferrús M; García-Azorín D; Molina-Martínez IFJ; Beltrán-Blasco I; Santos-Lasaosa S; Latorre G; Gago-Veiga AB; Láinez JM; Porta-Etessam J; Nieves-Castellanos C; Mínguez-Olaondo A; López-Bravo A; Quintas S; Morollón N; Díaz-Insa S; Belvís R; Irimia P
Neurologia (Engl Ed); 2024 Feb; ():. PubMed ID: 38431253
[TBL] [Abstract][Full Text] [Related]
12. The prospects of minocycline in multiple sclerosis.
Chen X; Ma X; Jiang Y; Pi R; Liu Y; Ma L
J Neuroimmunol; 2011 Jun; 235(1-2):1-8. PubMed ID: 21565409
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
14. [A review of multiple sclerosis (1). Presentation of a case].
Martinez-Altarriba MC; Ramos-Campoy O; Luna-Calcaño IM; Arrieta-Antón E
Semergen; 2015; 41(5):261-5. PubMed ID: 25241121
[TBL] [Abstract][Full Text] [Related]
15. [The BCTRIMS expanded consensus on treatment of multiple sclerosis: II. The evidences for the use of glucocorticoids and immunomodulatory treatments].
Moreira MA; Lana-Peixoto MA; Callegaro D; Haussen SR; Gama PD; Gabbai AA; Rocha FC; Lino AM;
Arq Neuropsiquiatr; 2002 Sep; 60(3-B):875-80. PubMed ID: 12364966
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
Sellebjerg FT; Sørensen PS;
Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
[No Abstract] [Full Text] [Related]
17. Disease-modifying drugs for multiple sclerosis: current and future aspects.
Freedman MS
Expert Opin Pharmacother; 2006 Oct; 7 Suppl 1():S1-9. PubMed ID: 17020427
[TBL] [Abstract][Full Text] [Related]
18. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Slof J; Gras A
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
[TBL] [Abstract][Full Text] [Related]
19. [Combined therapy in multiple sclerosis].
García-Merino JA; Blasco-Quítez MR; Ortiz-Benítez P; Puerta C
Rev Neurol; 2003 Mar 16-31; 36(6):545-9. PubMed ID: 12652419
[TBL] [Abstract][Full Text] [Related]
20. New and emerging disease modifying therapies for multiple sclerosis.
Saidha S; Eckstein C; Calabresi PA
Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
